Who are Thalidomide, Melphalan, Prednisone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Melphalan, Prednisone and Thalidomide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/thalidomide-melphalan-prednisone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Thalidomide, Melphalan, Prednisone — Competitive Intelligence Brief

Thalidomide, Melphalan, Prednisone (Thalidomide, Melphalan, Prednisone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy with immunomodulatory agent. Area: Oncology.

phase 3 Combination chemotherapy with immunomodulatory agent Multiple targets: cereblon (thalidomide), DNA (melphalan), glucocorticoid receptor (prednisone) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Thalidomide, Melphalan, Prednisone (Thalidomide, Melphalan, Prednisone) — Grupo de Estudos Multicentricos em Onco-Hematologia. This combination uses thalidomide as an immunomodulatory agent, melphalan as an alkylating chemotherapy, and prednisone as a corticosteroid to treat multiple myeloma through multiple mechanisms including immune activation, DNA damage, and anti-inflammatory effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Thalidomide, Melphalan, Prednisone TARGET	Thalidomide, Melphalan, Prednisone	Grupo de Estudos Multicentricos em Onco-Hematologia	phase 3	Combination chemotherapy with immunomodulatory agent	Multiple targets: cereblon (thalidomide), DNA (melphalan), glucocorticoid receptor (prednisone)
Melphalan, Prednisone and Thalidomide	Melphalan, Prednisone and Thalidomide	Gruppo Italiano Studio Linfomi	phase 3	Combination chemotherapy with immunomodulatory agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy with immunomodulatory agent class)

Grupo de Estudos Multicentricos em Onco-Hematologia · 1 drug in this class
Gruppo Italiano Studio Linfomi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thalidomide, Melphalan, Prednisone — Competitive Intelligence Brief. https://druglandscape.com/ci/thalidomide-melphalan-prednisone. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab